Collaborate with Us

REPRIEVE and the ACTG Network are issuing a collaborative Request for Proposals (RFP). The RFP will be open to investigators at REPRIEVE sites (both ACTG and REPRIEVE protocol-specific sites). Currently, this request is limited to data, including clinical data and currently available lab and biomarker data. Requests for samples may be considered in a future RFP.

Please review this page in detail for instructions and resources related to this RFP. Available resources include the REPRIEVE protocol (which contains a schedule of evaluations), the REPRIEVE Manual of Procedures (MOPS), the REPRIEVE Publications Standard Operating Procedures (SOP), available labs and biomarkers, baseline characteristics of REPRIEVE participants and available clinical outcomes, and dataset availability. 

This RFP will take place in two stages. First, investigators will submit a Letter of Intent (LOI) via the ACTG website by 11:59 PM EST on December 10, 2024. If there are overlapping LOIs submitted, investigators with such LOIs will be contacted by the ACTG to facilitate possible collaboration. Meritorious projects identified in the initial LOI review phase will be selected for the second phase of the review process, which will include a full proposal application process. Investigators with such LOIs will receive further instructions to submit a full proposal.

Second, investigators will submit a proposal via the ACTG website by April 1st, 2025 (provisional timeline). Up to approximately 7-10 meritorious proposals will be selected, based on scientific importance, availability of data, nonoverlap with any past, current or planned proposals, feasibility, and robustness of the statistical plan.

Decisions will be announced in May 2025. Depending on data availability and resources, subsequent RFP’s may be issued for REPRIEVE data. Highly ranked projects not accepted in the first RFP may be resubmitted in a subsequent RFP for REPRIEVE data sharing. The REPRIEVE Publications SOP outlines requirements and next steps for subsequent manuscript development.

Please review the list of current projects approved and under development by the REPRIEVE team, the REPRIEVE Ancillary Studies, and past REPRIEVE manuscripts before beginning a submission for this RFP and to ensure that there is not overlap with a past or ongoing REPRIEVE project. The current projects below largely represent prespecified Aims of the original REPRIEVE grant, supplementally funded Aims, and/or planned investigations of relevant areas of interest. Proposals submitted through this RFP for projects that were completed or are already underway cannot be approved. However, REPRIEVE will continue to solicit interest and create opportunities for site investigators to join the authorship teams of existing projects. To express interest in joining an existing project or if you have questions regarding overlap with a current REPRIEVE project, please contact the REPRIEVE Team (mghreprievetrial@mgb.org). 

Authorship: The lead author will submit a list of potential co-authors based on contribution and/or planned contribution with the initial proposal to the ACTG. For accepted proposals, at least one REPRIEVE Chair and Vice Chair and additional co-authors (based on contribution to the main trial, expertise, and equitable sharing of opportunities) will be assigned to each proposal and subsequent manuscripts. The final list of authors and author order will be approved by the REPRIEVE Publications and Executive Committees. All authors must meet ICMJE authorship requirements. Further details about authorship can be found in the REPRIEVE Publications SOP.

Statistical Analysis and Support: Proposals should outline the plan for statistical analysis and the sources of support for this plan. For example, does the proposal envision analysis of the data by a statistician outside of REPRIEVE, and if so, what is the level of experience of the statistical team and funding source for this analysis. Alternatively, does the proposal envision the analysis to be coordinated through the REPRIEVE Data Coordinating Center (DCC) / Center for Biostatistics in AIDS Research (CBAR), and if so, what will the funding source be, e.g. application for an external grant, ACTG SDAC application, or another source. In all cases, the proposed effort and methodologies to be used for the statistical analysis must be outlined. If a full proposal is under consideration for approval, proposers will be given an opportunity to estimate statistical effort with the REPRIEVE statistical core. If a statistical analysis is to occur at an outside institution, the analysis and proposed statistical team must be approved by the REPRIEVE statistical core, with sources of support outlined.

Institutional Review Board (IRB) and Data Use Agreement (DUA) Requirements: The proposals accepted from this RFP will be subject to the approval of relevant regulatory and contractual requirements. Investigators who propose to receive data to conduct secondary analyses will need to contact their institution’s IRB about the need for IRB submission. Data Use Agreements (DUA) must be executed in compliance with the NIH Data Management and Sharing Policy, the Federal Awarding Agency’s data sharing and access requirements, and MGB policies. 

DUAs will be executed between Mass General Brigham (MGB) and the investigator's institution to govern the sharing and use of data. There are two categories of DUAs: low-risk and high-risk.

1. Low-Risk DUA: This agreement applies to non-profit United States entities and involves data exchanges that meet specific criteria to ensure minimal risk to privacy and confidentiality. The following conditions apply: 
   1. Recipient Type: Non-profit U.S. entity.
   2. Institutional Review Board (IRB) or Human Research Committee Approval: The institution’s IRB or Human Research Committee must have reviewed and approved the data exchange or issued an exemption determination.
   3. Data Type: The data shared must be classified as either a Limited Data Set or De-identified Data. (Click here to view a chart that defines De-identified and Limited Data).
   4. Details of Exchange: The exchange of data must meet specific conditions, including not being used for machine learning or artificial intelligence purposes, or for the development or improvement of tangible intellectual property such as patentable inventions, medical devices, or software. A detailed list of requirements for the data exchange will be provided during the agreement discussions.
2. High-Risk DUA: This agreement applies to data exchanges that do not meet all the criteria for low-risk DUAs; including those involving international entities or organizations outside the United States.

Inquiries: Please send all inquiries to ACTGProposals@dlhcorp.com. For investigators with inquiries regarding the REPRIEVE Trial or proposal development, please email mghreprievetrial@mgb.org.

Click here for the REPRIEVE protocol

Click here for the REPRIEVE Manual of Procedures (MOPs)

Click here for the REPRIEVE Publications Standard Operating Procedures (SOP)

Click here for a Testing Completeness Report which includes available labs and biomarkers*

Click here for a list of baseline characteristics of REPRIEVE participants and available clinical outcomes

Click here for a list of the REPRIEVE analysis datasets

*The flow cytometry data is currently being analyzed, and as such, the data is not available at this time.